Dose Escalation: Optimizing Cohort Management in Early-Phase Development, Upcoming Webinar Hosted by Xtalks

In this free webinar, gain insight into the key considerations in selecting a dose escalation study design, including the evolution from 3+3 to more flexible Bayesian designs. Attendees will learn how proactive cohort management can reduce lag time between dosing decisions. The featured speakers will discuss the role and impact of safety and dose-escalation committees. Attendees will learn how real-time collaboration with clinical pharmacology supports faster decisions, including guidance from model-informed drug development support. The speakers will also share best practices for monitoring and managing dose-limiting toxicities (DLTs) in early-phase trials.

TORONTO, July 30, 2025 /PRNewswire/ -- In early-phase drug development, the success of a dose escalation study depends not only on the design but also on the speed and accuracy of decision-making across cohorts. Delays in progressing between dosing levels can extend timelines, increase costs and complicate data interpretation. This webinar examines how proactive cohort management — based on close coordination between clinical operations, safety committees and clinical pharmacology — can streamline early-phase studies and support more confident, data-driven decisions.

The speakers will discuss various dose escalation study designs, the role of internal and external review committees and strategies for managing dose-limiting toxicities (DLTs). The speakers will also highlight the evolving role of clinical pharmacologists, who no longer simply deliver PK results but also actively contribute to ongoing dose decisions in real time. Drawing on real-world experiences, the panel will share how proactive planning, ongoing monitoring and team-wide alignment can accelerate escalation and optimize early-phase trial outcomes.

Register now to discover how effective dose escalation strategies and proactive cohort management can accelerate early-phase trial outcomes and improve decision-making in clinical studies.

Join experts from Allucent, Brian Abbott, MD, Executive Medical Director, Therapeutic Area Medical Lead, Oncology/Hematology; Sandra Olthaf, MSc (Biomedical Science), Global Operations Head, Oncology/Hematology; Rachel Kudgus Lokken, PhD (Chemistry/Clinical Pharmacology), Senior Director, Clinical Pharmacology; and Titia Tjeenk Willink, MSc (Biomedical Science), Sr. Project Director, Global Project Leadership, for the live webinar on Thursday, August 21, 2025, at 11am EDT (5pm CEST/EU-Central).

For more information, or to register for this event, visit Dose Escalation: Optimizing Cohort Management in Early-Phase Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/

View original content to download multimedia:https://www.prnewswire.com/news-releases/dose-escalation-optimizing-cohort-management-in-early-phase-development-upcoming-webinar-hosted-by-xtalks-302516541.html

SOURCE Xtalks